Gene therapy of malignant glioma: Recent advances in experimental and clinical studies

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1155-1166

  Sasaki, M ^a   Plate, K H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Gene therapy; Malignant glioma

Indexed keywords

6 O METHYLGUANINE; 6 THIOXANTHINE; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DIHYDROFOLATE REDUCTASE; DNA METHYLTRANSFERASE; ETHYLNITROSOUREA; FLUCYTOSINE; GANCICLOVIR;

ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; CANCER IMMUNOTHERAPY; CHROMOSOME 17P; CLINICAL TRIAL; GENE AMPLIFICATION; GENE TECHNOLOGY; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE THERAPY; GLIOMA; HUMANS;

EID: 0031743934     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008488709359     Document Type: Review

References (101)

1. Vandenberg SR. Current diagnostic concepts of astrocytic tumors. J Neuropathol Exp Neurol 1992; 51: 644-57.
2. Berger MS, Leibel SA, Levin VA et al. Primary central nervous system tumors of the supratentorial compartment. In Levin VA (ed): Cancer in the Nervous System. London: Churchill Livingstone 1996; 57-126.
3. Saleman MS, Scholtz H, Kaplan RS et al. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994; 34: 213 20.
4. Davis FG, Freels S, Gutsch J et al. Survival rates in patients with primary malignant brain tumors stratified by patients age and tumor histological type: An analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 1998;88: 1-10.
5. Anderson F, Blaese RH. Culver KW. Treatment of severe combined immunodefieciency disease (SCID) due to adenosine deaminase (ADA) deficiency with autologous lymphocytes transduced with a human ADA gene. Hum Gene Ther 1990; 1: 331-61.
6. Ross G, Erickson R, Knorr D et al. Gene therapy in the United States: A five-year status report. Hum Gene Ther 1996; 7: 1781-90.
7. ORDA report. Hum Gene Ther 1996; 7: 685-9.
8. Culver KW, Ram Z, Wallbridge S et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
9. Featon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypass T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
10. Gansbacher B, Bannerji R, Daniels B et al. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity Cancer Res 1990; 50: 7820-5.
11. Itaya T, Yamagiwa S, Okada F et al. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Res 1987; 47: 3136-40.
12. Tepper RI, Pattengale PK, Leder P. Murine Interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-12.
13. Topp MS, Papadimitriou CA, Eitelbach F et al. Recombinant human Interleukin-4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995; 55: 2173-6.
14. Kuppner MC, Sawamura Y, Hamou MF et al. Influence of PGE2 and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2 activated lymphocytes. J Neurosurg 1990: 72: 619-25.
15. Roszman T, Elliott L, and Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991: 12: 370-4.
16. Fakhrai H, Dorigo O, Shawler D. L et al. Eradication of established intracranial rat gliomas by transforming growth factor-b antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-14.
17. Resnicoff M, Sell C, Rubini M et al. Rat glioblastoma cells expressing an antisense DNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218-22.
18. Trojan J, Blossey BK. Johnson TR et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulun-like growth factor I. Proc Natl Acad Sci USA 1992; 89: 4874-8.
19. Trojan J, Johnson TR, Rudin SD et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor-1 RNA. Science 1993; 259: 94-6.
20. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther 1995; 2: 235-44.
21. Moolten FL, Drug sensitivity (suicide) gene for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-87.
22. Culver KW, Van Gilder J, Link CJ et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase. Hum Gene Ther 1994; 5: 343-77.
23. Izquierdo M, Martin V, Felipe P et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSV-TK) ganciclovir gene therapy. Gene Ther 1996; 3: 491-5.
24. Ram Z. Culver KW. Wallbridge S et al. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 1993; 79: 400-7.
25. Ram Z, Culver K, Walbridge S et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-8.
26. Short MP, Choi BC, Lee JK et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-39.
27. Dong Y, Wen P, Manome Y et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizer glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713-20.
28. Huber BE, Austine EA, Good SS et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993: 53: 4619-26.
29. Mullen CA, Kilstrup M, Blaese MR et al. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selective system. Proc Natl Acad Sci USA 1992; 8: 33-7.
30. Ono Y, Ikeda K, Wei MX et al. Regression of experimental brain tumors with 6-Thioxanthine and Escherichia coli gpt gene therapy. Hum Gene Ther 1997; 8: 2043-55.
31. Borrelli E, Heyman R, Hsi M et al. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7572-6.
32. Ezzeddine ZT, Martuza RL, Platika D et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. N Biol 1991; 3: 608-14.
33. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-81.
34. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
35. Wu JK, Cano WG. Meylaerts S et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 1994; 35: 1094-104.
36. Freeman SM, Abbond CN, Whartenby K et al. The 'bystander effect' tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83.
37. Namba H, Iwadate Y, Tagawa M et al. Evaluation of the bystander effect in experimental brain tumors bearing HSV-TK gene by serial MRI. Hum Gene Ther 1996; 7: 1847-52.
38. Elshami,AA. Saavedra A, Zhang H et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85 92.
39. Li W, Parysck LM, Warnick R et al. In vitro evidence that metabolic corporation is responsible for the bystander effect obscured with HSV-TK retroviral gene therapy. Hum Gene Ther 1993; 4: 725-31.
40. Colombo BM, Benedetti S, Ottolenghi S et al. The 'Bystander effect': Association of U-87 cell death with ganciclovir mediated apoptosis of nearby cells and lack in athymic mice. Hum Gene Ther 1995: 6: 763-72.
41. Barba D, Hardin J, Sadelan M et al. Development of anti-tumor immunity following thymidiae kinase mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-52.
42. Topscott SJ, Miller AD, Olson JM et al. Gene therapy of rat 9L gliosarcoma tumor by transduction with selective genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-9.
43. Ram Z. Woldbridge S, Shawker T et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-60.
44. Barba D, Hardin J, Ray J et al. Thymidine kinase mediated killing of rat brain tumors. J Neurosurg 1993; 79: 729-35.
45. Izquierdo M, Cortes M. DeFelipe P et al. Lung-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 1995; 2: 66-9.
46. Oldlield EH, Ram Z, Culver KW et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-69.
47. Rainov NG, Kramm CM, Aboody-Guterman K et al. Retrovirus mediated gene therapy of experimental brain neoplasms using the herpes simplex virus thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996: 3: 99-106.
48. Takamiya Y, Short MP. Ezzeddine ZD et al. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type-1 thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992: 33: 493 503.
49. Strawn LM, McMahon G, App H et al. Flk-I as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-54.
50. Vile RG, Nelson JA, Castleden S et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component. Cancer Res 1994: 54: 6225-34.
51. Ram Z, Woldbridge S, Heiss JD et al. In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors. J Neurosurg 1994; 80: 535-40.
52. Benedetti S, Dimeco F, Pollo B et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspective for the combined transduction of the Interleukin-4 gene. Hum Gene Ther 1997; 8: 1345 53.
53. Kim JH, Kim SH, Kolozsvary A et al. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents, Int J Radiat Oncol Biol Phys 1995; 33: 861-8.
54. Chen SH, Shine HD, Goodman JC et al. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-7.
55. Maron A, Gustin T. Roux AL et al. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene; long term follow-up by MRI. Gene Ther 1996; 3: 315-22.
56. Perez-Cruet MJ, Trask TW, Chen SH et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 1994; 39: 506-11.
57. Vincent AJ, Esandi MC, Avezaat CJ et al. Preelinical testing of recombinant adenoviral Herpes simplex virus thymidine kinase gene therapy for CNS malignancies. Neurosurg 1997: 41: 442-52.
58. Shewach DS, Zerbe LK. Hughes TL et al. Enhanced cytoloxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rats glioma cells. Cancer Gene Ther 1994; 1: 107-12.
59. Vincent AJ, Vogels R, Someren GV et al. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum Gene Ther 1996; 7: 197-205.
60. Vrionis FD, Wu JK, Qi P et al. Prevention of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-TK) modified tumor cells. J Neuro-Oncol 1996; 30: 225-36.
61. Cool V, Pirotte B, Gerard C et al. Curative potential of Herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther 1996; 7: 627-35.
62. Ram Z, Culver KW, Oshiro E et al. Summary of results and conclusion of the gene therapy of malignant brain tumor: Clinical study. J Neurosurg 1995;82: 343A.
63. Van Meir EG, Polverini PJ. Chazin VR et al. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171-6.
64. O'Rourke DM, Qian X, Zhang H-T et al. Transreceptor inhibition of human glioblastoma cells by erbB family ectodomains. Proc Natl Acad Sci USA 1997; 94: 3250-5.
65. Redemann N, Holzmann B, Von Ruden T et al. Anti-oncogenic activity of signaling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992; 12: 491 8.
66. Hanania EG, Fu S, Roninson I et al. Resistence to toxic chemotherapy produced in mouse marrow cells by safety modified retroviruses containing a human MRD-1 transcription unit. Gene Ther 1995; 2: 279 84.
67. Sovrentino BP, Branott SJ, Bodine D et al. Selection of drugresistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science 1992; 257: 99 103.
68. Nagane M, Asai A, Shibui S et al. Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant glioma. Neurosurg 1997: 41: 434-41.
69. Weller M, Malipiero U. Rensing-Ehl A et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995; 55: 2936-44.
70. Nitta T & Sato K. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxy-nucleotides in human glioma cells. Neurosurg 1994; 34: 309-15.
71. Redekop GJ, Naus CG. Transduction with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 1995; 82: 83-90.
72. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature (London) 1992; 359: 845 8.
73. Shwciki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (London) 1992; 359: 843- 5.
74. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-84.
75. Millauer B, Shawver LK. Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 1994; 367: 576-9.
76. Kendal RL, Thomas KA Inhibition of vascular endothelial cell growth factor activity by an endogeneously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-9.
77. Cheng SY, Huang HJ, Nagone M et al. Suppression of glioblastoma angiogenecity and tumorigenicity by inhibition of endogeneous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-7.
78. Salah M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense VEGF sequences. Cancer Res 1996; 56: 393-401.
79. Plate KH. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metas Rev 1996; 15: 237-40.
80. Chambers R, Gillespie GT, Soroceanu L et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-5.
81. Markert JM, Malick A, Coen DM et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants retains susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
82. Martuza RL, Malick A, Markert JM et al. Experimental therapy of human glioma by means of genetically engineered virus mutant. Science 1991: 252: 854-6.
83. Mineta T, Rabkin SD, Martuza RL et al. Treament of malignant gliomas using ganciclovir hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-6.
84. Takamiya Y, Short MP, Moolten FL et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79: 104-10.
85. Kunwar S, Pai LH, Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 1993; 79: 569-76.
86. Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 3(12): 1354-61.
87. Recombinant DNA Advisory Committee. Regulatory issues. Hum Gene Ther 1995; 6: 1065-124.
88. Oldfield EH, Ram Z. Clinical protocol: Intrathecal gene therapy for the treatment of lepromeningeal carcinomatosis (phase 1-11 study) Hum Gene Ther 1995; 6: 55-85.
89. Kramm CM, Rainov NG, Sene-Esteves M et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 1996; 7: 1989-94.
90. Ram Z, Wallbridge S, Oshiro EM et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994; 54: 2141-5.
91. Vincent AJ, Esandi MD, Someren G et al. Treatment of leptomeningeal metastases in rat model using a recombinant adenovirus containing the HSV-TK gene. J Neurosurg 1996; 85: 648-54.
92. Eck SL, Alavi JB, Alavi A et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5010RSVTK: A phase 1 trial. Hum Gene Ther 1996; 7: 1465-82.
93. Okada H, Miyamura K, Itoh T et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther 1996; 4: 957-64.
94. Zhu J, Zhang L, Hanisch UK et al. A continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther 1996; 3: 472-6.
95. Yoshida J, Wakabayashi T, Mizuno M et al. Cytokine gene therapy of malignant glioma by means of DNA/Liposomes. In Nagai M (ed): Brain Tumor: Research and Therapy. Tokyo: Springer 1995; 423-34.
96. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-6.
97. Pillard F. Commentary: Promotor attenuation in gene therapy. Causes and remedies. Hum Gene Ther 1997; 8: 2009-10.
98. Zlokovic BV, and Apuzzo MLJ. Cellular and molecular neurosurgery: Pathway from concept to reality-Part II. Neurosurgery 1997; 40: 805-13.
99. Gage FH, Ray J and Fisher LJ. Isolation, characterization and use of stem cells from the CNS. Annu Rev Neurosci 1995; 18: 159 92.
100. Groves, Barnett SC, Franklin RJM et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993; 362: 453-5.
101. Morantz RA, Wood GW, Foster M et al. Macrophages in experimental human brain tumors. J Neurosurg 1979; 50: 298-304.